摘要
为观察马来酸曲美布汀胶囊联合双歧杆菌四连活菌片治疗腹泻型肠易激综合征的临床疗效，将96例肠易激综合征患者随机分为治疗组和对照组，每组48例。治疗组采用口服马来酸曲美布汀胶囊、双歧杆菌四连活菌片治疗；对照组仅采用口服马来酸曲美布汀胶囊治疗。疗程均为4周。结果显示，治疗组与对照组总有效率分别为87．5％和69．7％，治疗组疗效高于对照组，两组比较有显著性差异（P〈0．05）。结果表明，马来酸曲美布汀胶囊联合双歧杆菌四连活菌片治疗腹泻型肠易激综合征有较好的临床疗效。
In order to observe the efficacy of trimebutine maleate capsule plus live combined bifidobacteri-um for diarrhea-predominant irritable bowel syndrome（IBS-D）,96 cases were randomly divided into treat-ment group and control group, 48 cases for each. Treatment group received trimebutine maleate capsule plus live combined bifidobacterium orally, while control group trimebutine maleate capsule alone. Both groups were all treated for 4 weeks. The results showed that the total effective rate was 87.5% and 69.7% in treatment group and control group respectively, and there was significant difference between the two groups（ P 〈 0.05）. It is concluded that trimebutine maleate capsule plus live combined bifidobacterium is effective for IBS-D.
出处
《中国肛肠病杂志》
2013年第3期49-50,共2页
Chinese Journal of Coloproctology
